[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Stakeholder](https://github.com/mm80843/T3.5/tree/pages/docs/Stakeholder/index.md) >> Individual ID:PBN__Stakeholder_124 

# __Pharmaceutical companies__

## Category to which it belongs

* [A comprehensive array of various organizations and governing bodies related to diverse industries and sectors.](https://github.com/mm80843/T3.5/blob/pages/PBNCategory/PBN__PBNCategory_279.md)

## Closest similar item

* [Companies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_1905.md)
* [Company](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_1389.md)
* [Corporations](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_67.md)
* [Drug developers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_1482.md)
* [Manufacturing companies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_717.md)
* [Medical industry](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_1440.md)
* [Pharmaceutical company](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_388.md)
* [Pharmaceutical industry](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_420.md)
* [Pharmacies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_1148.md)
* [Technology companies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_1196.md)

## Risk affecting this stakeholder

* [Delayed drug development](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1783.md)
* [Development of ai-created drugs without comprehensive understanding of potential side effects](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6684.md)
* [Impact on pharmaceutical industry and supply chain](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6685.md)
* [Inaccurate identification of potential drugs for clinical trials](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6686.md)
* [Insecticide and drug resistance](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9449.md)
* [Lack of effective pharmaceutical interventions for new strains of pandemics](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10851.md)
* [Lack of specific medicine or vaccine to control covid-19.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_11050.md)
* [Misidentification or misinterpretation of clinical trial outcomes by ai, leading to incorrect drug development decisions.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17062.md)
* [Repurposing existing drugs without sufficient evidence for effectiveness against covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17496.md)
* [Unregulated promotion of drugs based on information extracted from ontologies](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17680.md)
* [Use of ai in drug discovery for contagious diseases without thorough validation and testing](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_19048.md)
* [Using ai algorithms to design new molecules or repurpose drugs may lead to unforeseen side effects or interactions with existing medications.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_19950.md)

## Risks that can be mitigated by this stakeholder

* [Absence of approved therapy for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1733.md)
* [Absence of covid-19 treatment and delayed availability of vaccine](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1341.md)
* [Antiviral drugs, if present in low levels in the environment, could cause irreversible effects to viral genomes, leading to resistance.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1849.md)
* [Challenges in achieving resilience in medication delivery](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1483.md)
* [Challenges in scalability, manufacturing costs, and accessibility of covid-19 vaccines](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2277.md)
* [Community transmission leading to large outbreaks and high number of incidents and deaths](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1528.md)
* [Consolidation of biomedical data for predictive drug combination therapies](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2085.md)
* [Continued evolution and mutation of influenza viruses](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2165.md)
* [Covid-19 outbreak and its impact on global healthcare systems](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1139.md)
* [Delay in developing an effective vaccine for covid-19.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_430.md)
* [Delay in the development of a commercially viable vaccine for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1885.md)
* [Delayed development and evaluation of safe and effective treatments](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1151.md)
* [Dependency on the development of a vaccine](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_431.md)
* [Development of ai-created drugs without comprehensive understanding of potential side effects](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_3417.md)
* [Development of drugs](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_3435.md)
* [Development of new drugs and antibodies may not cover all variations of the human coronavirus, leading to gaps in treatment options.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_4053.md)
* [Emergence of new variants of sars-cov-2](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_4153.md)
* [Estimates imply that the populations in europe are not close to herd immunity.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_4458.md)
* [Existing remedies being re-purposed to combat covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_4481.md)
* [Expectations for vaccine](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_4582.md)
* [Exposure to cuprous oxide as a pesticide and marine antifoulant](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_4985.md)
* [Global spread of covid-19 leading to significant confirmed cases and deaths](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5028.md)
* [Global threat from respiratory viruses such as sars, sars-cov-2, influenza, and tuberculosis tb .](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5037.md)
* [High mutation rates of rna viruses may lead to rapid adaptation and spread in new host populations.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5048.md)
* [Highly resistant variants of covid-19 continue to emerge](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5049.md)
* [Hoarding of vaccines](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5178.md)
* [Identification and classification of the novel covid-19 virus](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5182.md)
* [Identification of drugs with potential anti-coronavirus effects](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5415.md)
* [Impact on pharmaceutical industry and supply chain](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5484.md)
* [Inaccurate identification of potential drugs for clinical trials](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_5678.md)
* [Inadequate evaluation of drug therapies for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6325.md)
* [Inadequate vaccination coverage and acceptance in local communities](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6554.md)
* [Ineffective cure or treatment for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6559.md)
* [Ineffectiveness of single measures such as vaccines or antivirals in interrupting the spread of influenza](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6582.md)
* [Insecticide and drug resistance](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6593.md)
* [Integration of virus, human proteins, antiviral drugs, and diseases data increases the risk of unintentional release of sensitive information.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6684.md)
* [Investigation of new drugs for covid-19 therapy, such as tocilizumab and ace2-targeted treatments, may have unknown side effects and long-term impacts.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6685.md)
* [Lack of access to pharmaceutical interventions](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6686.md)
* [Lack of capacity for local vaccine production](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6690.md)
* [Lack of coronavirus vaccine](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_6899.md)
* [Lack of covid-19 vaccine](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7125.md)
* [Lack of cure or vaccine for tuberculosis](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7126.md)
* [Lack of detailed analysis on visitorsâ€™ attributes](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7128.md)
* [Lack of drug therapy options](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7129.md)
* [Lack of drugs and vaccines](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_7766.md)
* [Lack of effective antiviral drug and vaccine](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_8113.md)
* [Lack of effective medical treatment for contagious diseases](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_8714.md)
* [Lack of effective pharmaceutical interventions for new strains of pandemics](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_8749.md)
* [Lack of effective treatment](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_8750.md)
* [Lack of effective treatment and vaccine](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9110.md)
* [Lack of effective treatment for baylisascariasis](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9447.md)
* [Lack of effective treatment for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_9599.md)
* [Lack of effective treatment for newly emerging infectious diseases such as covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10405.md)
* [Lack of effective vaccine for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10443.md)
* [Lack of evidence-based research on the recommended use of anti-inflammatory drugs for covid-19 treatment](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10544.md)
* [Lack of medication and vaccines for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10661.md)
* [Lack of novel treatment options](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10780.md)
* [Lack of preexisting immunities](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10784.md)
* [Lack of specific medicine or vaccine to control covid-19.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10851.md)
* [Lack of specific treatment or vaccine for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_10862.md)
* [Lack of specific treatments and vaccines for coronavirus infections](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_11050.md)
* [Lack of treatment or vaccine for sars-cov-2](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_11087.md)
* [Lack of vaccine and medications against covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_11412.md)
* [Lack of vaccine or cure](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_12077.md)
* [Lack of vaccine or specific drug treatment for covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_12078.md)
* [Lack of vaccines and agent-specific drugs](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_12110.md)
* [Lagging development of vaccines and medicine](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_13322.md)
* [Large stocks of vaccine not available for 18 months or more](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_14126.md)
* [Limited research on drug efficacy, safety, and antibody response](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_14254.md)
* [Limited utilization of ai technology in clinical trials and medicine development may slow down the process of achieving precise results and accelerating medicine and vaccine development.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_14269.md)
* [Little prospect of widely available vaccine and second global outbreak](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_14293.md)
* [Low levels of animal pharmaceuticals from large drug suppliers](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_14464.md)
* [Low percentage of individuals infected, with an attack rate on average of 4.9%.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_14713.md)
* [Mechanism of action of gbns against viruses](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_15395.md)
* [Misidentification or misinterpretation of clinical trial outcomes by ai, leading to incorrect drug development decisions.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_15802.md)
* [Misinformation leading to incorrect treatment and drug development](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_16435.md)
* [Need for treatments and approaches to combat specific viral proteins](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_16882.md)
* [No standard vaccine or cure for covid-19.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17046.md)
* [Non-pharmaceutical measures as a substitute for medical solutions](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17047.md)
* [Off-label use of favipiravir for sars-cov-2 treatment](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17062.md)
* [Opaque development of pandemic management technologies](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17064.md)
* [Pandemic events sars, h1n1, mers, ebola](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17101.md)
* [Parasite resistance to drugs and mosquito resistance to insecticides](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17496.md)
* [Potential spread of antibiotic-resistant bacteria due to misclassification of bacterial protective antigens bpas by ai in reverse vaccinology.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17516.md)
* [Predicted increase in cases without vaccine availability](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17517.md)
* [Prediction of unknown side effects leading to unforeseen health risks](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_17680.md)
* [Projects necessary for the delivery of health care services, such as hospitals, health-care facilities, and pharmaceutical manufacturing facilities.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_18053.md)
* [Rapid mutation of microorganisms and adaptation as a cause of human diseases](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_18175.md)
* [Rapid variation of some viruses](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_18189.md)
* [Rapidly developing drugs and vaccines for covid-19 by utilization of robots and cps technologies](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_18200.md)
* [Repurposing existing drugs without sufficient evidence for effectiveness against covid-19](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_18210.md)
* [Research institutions working 24/7 on drug and vaccine development](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_18905.md)
* [Rising cases of fungal and viral resistances posing significant threats](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_19021.md)
* [Risk of new variants and mutations](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_19047.md)
* [Serious pandemic viral infections such as sars and avian influenza](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_19048.md)
* [Shortage of opioid medications and lack of palliative care training for primary caregivers and health care professionals in emergency departments and intensive care units.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_19098.md)
* [Spread of disease](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_19568.md)
* [Treatment of covid-19 is mostly symptomatic](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_19590.md)
* [Unequal access to vaccines](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_19600.md)
* [Use of ai in drug discovery for contagious diseases without thorough validation and testing](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_19662.md)
* [Use of drugs with potential side effects for covid-19 treatment](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_19663.md)
* [Use of experimental and unapproved drugs for covid-19 treatment](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_19664.md)
* [Use of graphene oxide go as an effective virucide](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_19950.md)
* [Using ai algorithms to design new molecules or repurpose drugs may lead to unforeseen side effects or interactions with existing medications.](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_20038.md)
* [Vaccine distribution and storage](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_20754.md)
* [Virus binding to host cells via lock and key mechanism](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_20755.md)

## This Stakeholder belongs to this Stakeholder Group

* [Health organisations](https://github.com/mm80843/T3.5/blob/pages/StakeholderGroup/PBN__StakeholderGroup_7.md)
* [Private sector](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_57.md)

## This Stakeholder belongs to this Stakeholder Subgroup

* [Private health organisations](https://github.com/mm80843/T3.5/blob/pages/StakeholderSubgroup/PBN__StakeholderSubgroup_25.md)

## This Stakeholder can get these Benefits from mitigation measures

* [Accelerated drug testing](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_217.md)
* [Disease prevention](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_578.md)
* [Faster vaccine development](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_912.md)
* [Strengthened supply chain](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_682.md)
* [Tracking antimicrobial usage](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_661.md)

## This stakeholders can act on the following general blueprint(s)

* [Implementing Vaccination Strategies and Awareness Campaigns](https://github.com/mm80843/T3.5/blob/pages/aBlueprint/PBN__aBlueprint_11.md)

## Type of the stakeholder

* [At risk](https://github.com/mm80843/T3.5/blob/pages/Stakeholder_Type/PBN__Stakeholder_Type_0.md)
* [Beneficiary](https://github.com/mm80843/T3.5/blob/pages/Stakeholder_Type/PBN__Stakeholder_Type_2.md)
* [Risk owner](https://github.com/mm80843/T3.5/blob/pages/Stakeholder_Type/PBN__Stakeholder_Type_1.md)

